Novacta Biosystems Limited completes Phase I study of NVB302 against C. difficile infection in healthy volunteers

09-Aug-2012 - Celtic Pharma Holdings Advisors LLP announced that Novacta Biosystems Limited has completed a Phase I clinical trial of NVB302, the Company’s orally administered treatment for Clostridium difficile infection (“CDI”).Both single ascending dose and multiple ascending dose studies in a total of 64 ...

DSM to manufacture C. difficile compound for Novacta Biosystems

18-Jun-2010 - DSM BioSolutions announced that it has entered into an agreement with Novacta Biosystems Limited for the process development and cGMP production of its C. difficile molecule, a new class of lantibiotic compounds. DSM has successfully completed the process development and commenced ...

Novacta therapeutics and Oxygen Healthcare announce a multi FTE medicinal chemistry collaboration

14-Dec-2009 - Novacta Therapeutics and O2h announced a multi FTE chemistry collaboration to support their internal drug discovery efforts. This is the third successive collaboration over the last three years. “Following two very successful projects, we are excited to enter a third collaboration that combines ...

Cambridge Major To Partner with Novacta Biosystems

06-Apr-2009 - Cambridge Major Laboratories and Novacta Biosystems have announced a collaboration combining respective expertise in process development, custom synthesis and biocatalysis. Novacta will develop biocatalytic approaches to target chiral intermediates which CML will then scale-up in facilities in ...

Novacta Therapeutics Strengthens Leadership Team

Dr David Pompliano Appointed to the Board of Directors and as Chairman of the Scientific Advisory Board

26-Feb-2009 - Novacta Therapeutics Ltd announced the appointment of Dr David Pompliano to the Board of Directors. In addition to his role of non-executive director Dr. Pompliano will also provide strategic direction to Novacta’s R&D team and will hold the position of Chairman of the Scientific Advisory Board. ...

Novacta Therapeutics and UK Ministry of Defence Announce Collaboration to Discover Novel Antiviral Therapeutics

17-Nov-2008 - Novacta Therapeutics announced that the UK's Defence Science and Technology Laboratory (DSTL) will evaluate its proprietary lantibiotics as a broad spectrum antiviral treatment. Novacta’s lantibiotics have demonstrated potential as antibiotics in early preclinical studies. These naturally ...

Novacta receives £3.5 million strategic translation award from the Wellcome trust ot target C. difficile infections

16-Jan-2008 - Novacta Biosystems, a UK-based anti-infective therapeutics company, announced that the Wellcome Trust, the UK's largest medical research charity, has awarded it £3.5 million as part of the Trust's Strategic Translational Award programme. Novacta will use the award to progress development of a ...